The degree of repression of NRF2 determines the overall sensitivity of cancer cells towards the HER2 targeted therapies, an axis that could be modulated to further sensitise otherwise resistant ovarian cancer cells. This evidence concerns the gene ERBB2 and ovarian carcinoma.